pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Eli Lilly and Co · news · pharmadog
← back to Eli Lilly and Co
News mentioning Eli Lilly and Co
123
stories
Aug 14, 26
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
biopharma dive
Aug 13, 26
Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale
biospace
Aug 12, 26
Lilly cracks down on black market for obesity asset retatrutide with six lawsuits
biospace
Aug 12, 26
7 companies hiring in North Carolina now
biospace
Aug 12, 26
Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
biospace
Aug 12, 26
With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development
biospace
Aug 11, 26
Amgen lays groundwork for new R&D center in Hyderabad
fiercebiotech
Aug 10, 26
Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
biopharma dive
Aug 7, 26
Why Big Pharma is chasing the industry’s most-powerful supercomputer
biopharma dive
Aug 7, 26
STAT+: Pharmalittle: We’re reading about Replimune’s melanoma drug, a Medicare policy change, and more
stat
Aug 5, 26
Lilly confident in slow and steady Foundayo launch, as ex-US sales shine
biospace
Aug 5, 26
Lilly, FDA retatrutide biologic dispute comes to a head as submission nears
biospace
Aug 5, 26
Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1
biospace
Jul 31, 26
Lilly and Resilience invest $750M in diabetes and obesity drug device supply
biospace
Jul 30, 26
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
biopharma dive
Jul 30, 26
Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
biospace
Jul 28, 26
Altimmune rises as GLP-1/glucagon drug curbs heavy drinking in mid-stage study
biospace
Jul 27, 26
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
biospace
Jul 24, 26
Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
biospace
Jul 24, 26
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
biospace
Jul 23, 26
A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
stat
Jul 23, 26
Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data
biospace
Jul 23, 26
Make or break: Commercial hires critical for success
biospace
Jul 23, 26
Biopharma layoffs must double in H2 for 2026 to match 2025 cuts
biospace
Jul 22, 26
Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
biospace
Jul 20, 26
Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics
biospace
Jul 20, 26
Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
fiercebiotech
Jul 20, 26
Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independence
biospace
Jul 16, 26
Lilly makes up to $3.8B psychedelics play in AtaiBeckley takeover
biospace
Jul 16, 26
Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno
biospace
← prev
page 3 of 5
next →
